Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01361581

Acronym

Citrate

Enrollment

120

Registered

2011-05-27

Start date

2008-01-31

Completion date

Unknown

Last updated

2011-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Renal Failure, Critical Illness

Keywords

Acute renal failure, Anticoagulation, Citrate, Haemodiafiltration, Haemofiltration, Renal replacement therapy

Brief summary

Citrate anticoagulation is associated with metabolic side effects which are linked to a portion of citrate reaching systemic circulation. Data on significance of systemic gain of citrate and its relationship to method configuration are missing. Patient might also receive certain dose of lactate as a buffer and a dose of glucose if acid-citrate-dextrose solution is used. The authors test variable methods of indirect estimate of systemic dose of citrate which would allow to quantify the metabolic input without mostly unavailable measurements of citrate levels.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to No maximum

Healthy volunteers

Inclusion criteria

* Acute renal failure on continuous renal replacement therapy for more than 24 hours (CVVH or CVVHDF).

Exclusion criteria

* Absence of consent.

Countries

Czechia

Outcome results